Price (delayed)
$3.95
Market cap
$255.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$275.82M
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in
There are no recent dividends present for INZY.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.